Postrenal transplant malignancy: An update for clinicians

When compared to the general population, solid organ transplant patients had a 2–3 times higher overall risk of cancer. The third most frequent cause of mortality in kidney transplant patients is posttransplant malignancy, with certain malignancies (melanoma, renal cell carcinoma, and posttransplant...

Full description

Bibliographic Details
Main Authors: Renuka Soni, Priyadarshi Ranjan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Indian Journal of Transplantation
Subjects:
Online Access:http://www.ijtonline.in/article.asp?issn=2212-0017;year=2023;volume=17;issue=4;spage=389;epage=396;aulast=Soni
Description
Summary:When compared to the general population, solid organ transplant patients had a 2–3 times higher overall risk of cancer. The third most frequent cause of mortality in kidney transplant patients is posttransplant malignancy, with certain malignancies (melanoma, renal cell carcinoma, and posttransplant lymphoproliferative disease) occurring at significantly greater rates than in the general population. Longer lifespans for kidney transplant recipients necessitate close monitoring for posttransplant cancer. Immunosuppressant medicine and oncogenic infections appear to be significant factors in the development of cancer. With the existing arsenal of pharmacotherapy and the possibility for immunologic surveillance in the future, posttransplant treatment might be tailored to reduce the risk of posttransplant malignancy without affecting graft survival. This manuscript gives an outline of the occurrence, causative factors, surveillance, diagnosis, and treatment of posttransplant malignancy. The review focuses on the most prevalent cancers and the patients who are most at risk of developing them, including an overview of pathogenesis, the association of immunosuppressive medications with the development of cancer, and several proposed processes that explain why transplant recipients have a higher cancer risk.
ISSN:2212-0017
2212-0025